Key result
Between 2005 and 2015, prescription profiles in patients with polypharmacy showed major increases in PPIs, statins, antidepressants, and beta-blockers, while antiepileptic use almost tripled.
Why the study?
The study aimed to identify and compare medication profiles in populations with polypharmacy between 2005 and 2015.
Cross-Sectional
There were significant increases in the prescription of specific therapeutic subgroups, including cardiovascular and psychotropic medications, among patients with polypharmacy in Spain between 2005 and 2015.
May signal rising medication complexity in polypharmacy; leaves open drivers, appropriateness, and outcomes.
We aimed to identify and compare medication profiles in populations with polypharmacy between 2005 and 2015. We conducted a cross-sectional study using information from the Computerized Database for Pharmacoepidemiologic Studies in Primary Care (BIFAP, Spain). We estimated the prevalence of therapeutic subgroups in all individuals 15 years of age and older with polypharmacy (≥5 drugs during ≥6 months) using the Anatomical Therapeutic Chemical classification system level 4, by sex and age group, for both calendar years. The most prescribed drugs were proton-pump inhibitors (PPIs), statins, antiplatelet agents, benzodiazepine derivatives, and angiotensin-converting enzyme inhibitors. The greatest increases between 2005 and 2015 were observed in PPIs, statins, other antidepressants, and β-blockers, while the prevalence of antiepileptics was almost tripled. We observed increases in psychotropic drugs in women and cardiovascular medications in men. By patient´s age groups, there were notable increases in antipsychotics, antidepressants, and antiepileptics (15-44 years); antidepressants, PPIs, and selective β-blockers (45-64 years); selective β-blockers, biguanides, PPIs, and statins (65-79 years); and in statins, selective β-blockers, and PPIs (80 years and older). Our results revealed important increases in the use of specific therapeutic subgroups, like PPIs, statins, and psychotropic drugs, highlighting opportunities to design and implement strategies to analyze such prescriptions' appropriateness.
No takes yet. Share an insight, caveat, or question.
Rodríguez et al. (2021) conducted a cross-sectional in Polypharmacy. Polypharmacy was evaluated on Prevalence of therapeutic subgroups. Between 2005 and 2015, prescription profiles in patients with polypharmacy showed major increases in PPIs, statins, antidepressants, and beta-blockers, while antiepileptic use almost tripled.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: